Patients' characteristics phase I/II study: NK-DLI post haplo-SCT.

ALL: acute lymphatic leukemia, AML: acute myeloid leukemia, AR: autologous reconstitution, ass.: associated, ATG: anti-thymocyte globulin, BM: bone marrow, BW: kg/body weight, CC: complete chimerism, cCR: continuous complete remission, CD34: CD34 stem cell graft, CD3/19: CD3/CD19 depleted stem cell graft, CR: complete remission, d: days, DP: disease progression, EBV: epstein-barr-virus, Etop: etoposide, f: female, Flu: fludarabine, GF: graft failure, GvHD: graft-versus-host disease, haplo-SCT: haploidentical stem cell transplantation, m: male, MC: mixed chimerism, Mel: melphalan, MMF: mycophenolate-mofetil, NB: neuroblastoma, NK-DLI: NK cell donor lymphocyte infusion, No.: number, NR: non remission, n.s.: not specified, OKT3: Orthoclone/Muronomab, PB: peripheral blood, PR: partial remission, R: relapse, RMS: rhabdomyosarcoma, SCT: stem cell transplantation, T-DLI: T cell donor lymphocyte infusion, TBI: total body irradiation, Thio: thiotepa, Treo: treosulfan,*patients received both NK-DLIunstim and NK-DLIIL-2 stim,†died,#under detection limit,§difference statistically not significant.